Antibody directed against a tau-derived neurotoxic peptide and uses thereof

A method for the treatment and/or prevention of Alzheimer's disease (AD) or a non-AD tauopathy, comprising administering a monoclonal antibody, or an antigen binding fragment thereof, that binds to an antigen comprising the sequence QGGYTMHQDQ (SEQ ID No. 1) and possesses at least one biological activity selected from inhibition of pathological hyperphosphorylation of Tau, reduction of the most neurotoxic amyloid-precursor protein (APP)-derived Aβ species (monomer and low-molecular weight oligomers), increase in task-induced Arc expression when compared to a proper control, significant neuroprotection in at least one of two different hippocampal-based behavioural tasks (Novel object recognition (NOR) and Object Place Recognition (OPR)), prevention of the loss in dendritic spine density, reduction of neuro inflammation, and normalization of LTP changes to a patient in need thereof.